MedTrace Logo

Evaluation of Airway Gene Expression in COPD and Controlled Populations

NCT00571792 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 42

Last updated 2023-12-04

No results posted yet for this study

Summary

To explore potential proteins that may be used to develop novel therapies for COPD. This will be accomplished by acquiring material from the lower respiratory tract via endobronchial brushings.

Conditions

Sponsors & Collaborators

  • Wyeth is now a wholly owned subsidiary of Pfizer

    collaborator INDUSTRY

  • University of Nebraska

    lead OTHER

Principal Investigators

  • Stephen I Rennard, MD · University of Nebraska

Eligibility

Min Age
45 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-09-01
Primary Completion
2011-02-01
Completion
2011-02-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00571792 on ClinicalTrials.gov